Table 1.

CNS remyelination in mice after treatment with human Abs

Treatment	No. of mice	Area of white matter, mm2	Area of myelin pathology, mm2	Area of CNS type remyelination, mm2	Area of CNS-type remyelination, %
IVIg	10	8.60  ± 0.52	0.86  ± 0.10	0.13  ± 0.02	14.15  ± 2.38*
Human IgM	14	9.70  ± 0.43	1.21  ± 0.21	0.24  ± 0.04	23.19  ± 3.26†
sHIgM 1	4	9.34  ± 1.93	0.68  ± 0.07	0.03  ± 0.01	8.35  ± 3.73
sHIgM 2	4	8.78  ± 0.70	0.87  ± 0.12	0.10  ± 0.01	11.37  ± 1.30
sHIgM 14	7	11.01  ± 0.60	1.13  ± 0.18	0.08  ± 0.03	8.41  ± 2.59
sHIgM 22	8	10.55  ± 0.41	1.16  ± 0.22	0.19  ± 0.05	17.06  ± 3.42*
SHIgM 46	5	9.44  ± 0.36	0.66  ± 0.06	0.18  ± 0.04	27.12  ± 4.01‡
PBS	7	9.78  ± 0.60	1.20  ± 0.22	0.06  ± 0.02	6.74  ± 1.80

Values represent the mean ± SEM. One-way ANOVA and t test were used to compare the percent area of CNS-type remyelination in mice treated with human antibodies to mice treated with PBS. Such analysis revealed  

^*P < 0.05;  

^†P < 0.01,  

^‡P < 0.001. Comparison of mice treated with IVIg to other treatments revealed polyclonal human IgM P = 0.05, sHIgM 46 P < 0.05. All other comparisons were not statistically significant. There was no difference in the CNS-type remyelination between polyclonal human IgM, sHIgM 22, and sHIgM 46. Area of peripheral nervous system-type SC remyelination ranged from 0 to 0.08 mm². This corresponded to 0.0 to 6.92 percent area of peripheral nervous system-type SC remyelination as a function of myelin pathology. There was no statistical difference in the area of myelin pathology in the various treatment groups compared to PBS or in the peripheral nervous system-type SC remyelination between groups.